Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
3 hedge funds and large institutions have $948K invested in Loncar China BioPharma ETF in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.
34% less capital invested
Capital invested by funds: $1.44M → $948K (-$493K)
57% less funds holding
Funds holding: 7 → 3 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$767K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$45K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$21.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$11K |
| 5 |
Citigroup
New York
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $876K | -$767K | -28,891 | -50% |
|
2
Morgan Stanley
New York
| $61K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $11K | -$21.4K | -805 | -70% |
|
|
4
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$45K | -2,000 | Closed |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| – | -$11K | -500 | Closed |
|
|
6
Citigroup
New York
| – | -$9K | -390 | Closed |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -100 | Closed |
|
CHNA Hedge Fund Activity: Q2 2020 in Review
3 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q2 2020, worth a combined $948K — down 34% from $1.44M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CHNA and 0 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Jane Street, cutting an estimated $767K.
- 3 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q2 2020, down from 7 in Q1 2020.
- Funds reported $948K of Loncar China BioPharma ETF stock for Q2 2020, down 34% quarter-over-quarter.
- 0 funds opened new Loncar China BioPharma ETF positions in Q2 2020 and 4 closed out, a net change of -4 holders.
- The largest Loncar China BioPharma ETF seller in Q2 2020 was Jane Street, an estimated $767K sold.
Based on aggregated 13F filings for Q2 2020.